Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy

  • Technology appraisal guidance
  • TA374
  • Published: 

Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175): evaluation report (August 2014)

Contents:

01. C&C comments on the first ACD – AstraZeneca

02. C&C comments on the first ACD – Roche

03. C&C comments on the first ACD – British Thoracic Oncology Group

04. C&C comments on the first ACD – National Lung Cancer Forum For Nurses

05. C&C comments on the first ACD – Royal College of Physicians

06. Comments on the Appraisal Consultation Document from Experts – Jfox

07. Comments on the ACD received through the NICE website

08. Addendum 1 to the Assessment Report

09. Addendum 2 to the Assessment Report

10. C&C comments on the Addendum 2 to the Assessment Report – Roche

11. C&C comments on the Addendum 2 to the Assessment Report – Roy Castle Lung Cancer Foundation

12. C&C comments on the Addendum 2 to the Assessment Report – Royal College of Physicians

13. C&C comments on the Addendum 2 to the Assessment Report – British Thoracic Oncology Group

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 07 August 2014